Investment-blog.net: Stocks, Emerging markets, Bonds, Currencies and Commodities

Since Stock Market has a big decline last week, particular in Friday, Most of stocks end up with red and investors are depressed about the market stock.
However, Point Therapeutics Inc. (POTP), a Healthcare firm which outperform last week since it has announced emerged with a private medical company DARA by Oct.10 2007. Even most [...]

Stocks Head Toward Lower Open As Credit, Housing, Profit Worries Escalate
NEW YORK (AP) — Wall Street pointed toward a lower open Monday as investors prepared to extend the sharp losses from Friday, when worries about the credit and housing markets and disappointing corporate earnings came to a head.
Stock markets around the world, responding to the [...]

That something might come from the technology sector, which has so far remained one of the strongest performers amid expectations that it remains somewhat shielded from a weak U.S. economy.
“Next week, we’re going to have a lot more earnings from other sectors, especially from the tech sector, which has been a strong performer, and also [...]

1. If you read the press release it says “Point and DARA believe that the proposed merger will qualify as a “reverse merger” under NASDAQ Marketplace Rule 4340. As a result, although Point’s common stock is currently listed on NASDAQ, DARA intends to file an initial listing application and satisfy all requirements for initial listing. [...]

3rd quarter SUPPORT/PORTING PRS
- Jul 09 2007 - Nexperia Semiconductors (VP6 & VP6)
- Aug 13 2007 - Flix (H.264)
- Aug 22 2007 - Akamai (VP6)
- Sep 27 2007 - Adobe ‘Moviestar’ (VP6-S)
3rd quarter CONTRACT/LICENSE/DEPLOYMENT PRS
- Aug 15 2007 - Inlet (VP6)
- Aug 20 2007 - Media [...]

Pursuant to the merger agreement, DARA will merge with a subsidiary of Point, with DARA surviving as a wholly-owned subsidiary of Point. After giving effect to the merger, DARA stockholders will hold 96.4% of Point’s outstanding shares of common stock on a fully-diluted basis, and Point will change its name to DARA BioSciences, Inc. and [...]

BUSINESS SUMMARY
Point Therapeutics, Inc., a development stage biopharmaceutical company, engages in the development of dipeptidyl peptidase (DPP) inhibitors for use in cancer and type 2 diabetes. Its DPP inhibitors are enzymes that regulate various physiological processes involved in tumor growth and host responses to cancer and type 2 diabetes. The company’s lead product candidate, talabostat [...]

POTP: The most spectacular run in recent memory. From 0.03 to new high 0.53 this morning. That’s near 1000% increase. Only if I know when it was still 0.03. Then again, who’d buy POTP then when liquidation was knocking the door.
You think the run is finish, not yet. Most board members here believe it will [...]

District-based InPhonic said yesterday that it was considering selling itself and had brought in Wall Street restructuring specialist Lazard to help assess that and other options. At the same time, the company said its third-quarter results would be lower than forecast. The stock fell 60 percent.
InPhonic, an online seller of wireless products and services, [...]

it’s new residual model. INPC over the last year has built up a huge residual income, one that Lazard can easily structure into profitability. The old management team churned and burned, but the new management team can look like heros. All that is needed is some financing. Chances of getting the financing are strong, based [...]

“The company was modeled after sites like Expedia, gathering information from companies into a single site to help customers find deals by comparing services and prices. Wireless carriers do business with InPhonic because acquiring a customer through the company can be less expensive than traditional marketing approaches designed to generate sales at a brick-and-mortar store. [...]

Latest news: Lazard to Expand Financial Advisory Business into the U.S. Middle Market Through Acquisition of Goldsmith Agio Helms
“The acquisition of Goldsmith Agio Helms will allow Lazard to extend our reach to the vibrant middle market for our existing client base,” said Kenneth M. Jacobs, CEO of Lazard North America. “The combination enables us [...]

“InPhonic, Inc. (NASDAQ:INPC - News), a leading online seller of wireless services and products, today announced that its Board of Directors has selected Lazard Middle Market to conduct, in conjunction with management, a full review of the Company’s financing and strategic alternatives to increase the Company’s cash liquidity and to maximize shareholder value. These alternatives [...]

So what is INPC worth?
1) This 10 year old company has reach an income of
$300 million per year.
2) They have $45 million debts.
3) Their market cap now is $23 million.
So you must think how much another compnay is prepare to pay for this company.
Normally companies like this can go 5 to 10 times their [...]

“Several of the world’s biggest banks are in talks to put up about $75 billion in backup financing that could be used to buy risky mortgage securities and other assets, a move designed to ease pressure on a crucial part of the credit markets that still looms over the broader economy.”
http://www.nytimes.com/2007/10/14/business/14bank.html?ref=business 
“But it also shows the [...]